Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial

Triplet regimens containing immunomodulatory drugs and proteasome inhibitors (PIs) have improved outcomes and extended survival for patients with relapsed/refractory multiple myeloma (RRMM). We evaluated updated health-related quality of life (HRQoL) findings from the phase 2 ELOQUENT-3 clinical tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Weisel, Katja, Dimopoulos, Meletios A., San-Miguel, Jesús, Paner, Agne, Engelhardt, Monika, Taylor, Fiona, Lord-Bessen, Jennifer, Yip, Christine, Greenwood, Mike, Tang, Jackson, Cavo, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970270/
https://www.ncbi.nlm.nih.gov/pubmed/36860268
http://dx.doi.org/10.1097/HS9.0000000000000843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970270/
https://www.ncbi.nlm.nih.gov/pubmed/36860268
http://dx.doi.org/10.1097/HS9.0000000000000843

Ejemplares similares